Fig. 7: In vivo biodistribution and phototherapeutic efficacy of NanoNMO.
a In vivo fluorescence imaging (excited at 640 nm, ×107 ps−1·cm−1·sr−1·μW−1·cm2, white ellipses representing the tumor area) and b in vivo photoacoustic imaging (excited at 690 and 700 nm, yellow ellipses representing the tumor area) of 4T1 tumor-bearing mice before and after intravenous injection of NMO or NanoNMO. c Quantitative fluorescence and photoacoustic intensities of the tumor sites after intravenous injection of NanoNMO. F.I., fluorescence intensity; PA.I., photoacoustic intensity. d Ex vivo fluorescence imaging of 4T1 tumor bearing mice injected with NMO and NanoNMO (×107 ps−1·cm−1·sr−1·μW−1·cm2) and e quantitative fluorescence intensities. H., heart; Li., liver; Sp., spleen; Lu., lung; K., kidney; T., tumor; Sk., skin. n = 3 biologically independent experiments for mice with similar results. Data were expressed as mean values ± SD. f Tumor growth plots of 4T1 tumor bearing mice following various treatments (***p < 0.0001). g Average body weight changes of mice after indicated treatments. n = 5 biologically independent experiments for mice. Data were expressed as mean values ± SD, ***p < 0.001, determined by two-tailed Student’s t test.
